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ABSTRACT  
 
 
Background & Aims: Approximately 75% of patients with suspected Lynch syndrome carry 
variants in MLH1 or MSH2—proteins encoded by these genes are required for DNA 
mismatch repair (MMR). However, 30% of these are variants of unknown significance 
(VUS). A assay that measures cell response to the cytotoxic effects of a methylating agent can 
determine the effects of VUS in MMR genes and identify patients with constitutional 
mismatch repair-deficiency syndrome. We adapted this method to test the effects of VUS in 
MLH1 and MSH2 genes found in patients with suspected Lynch syndrome.  
 
Methods: We transiently expressed MLH1 or MSH2 variants in MLH1- or MSH2-null human 
colorectal cancer cell lines (HCT116 or LoVo), respectively. The MMR process causes death 
of cells with methylation-damaged DNA bases, so we measured proportions of cells that 
undergo death following exposure to the methylating agent; cells that escaped its toxicity 
were considered to have variants that affect function of the gene product. Using this assay, we 
analyzed 88 variants (mainly missense variants), comprising a validation set of 40 previously 
classified variants (19 in MLH1 and 21 in MSH2) and a prospective set of 48 VUS (25 in 
MLH1 and 23 in MSH2). Prediction scores were calculated for all VUS according to the 
recommendations of the American College of Medical Genetics and Genomics, based on 
clinical, somatic, in silico, population and functional data. 
 
Results: The assay correctly classified 39/40 variants in the validation set. The assay 
identified 12 VUS that did alter function of the gene product and 28 VUS that did not; the 
remaining 8 VUS had intermediate effects on MMR capacity and could not be classified. 
Comparison of assays results with prediction scores confirmed the ability of the assay to 
discriminate VUS that affected the function of the gene products from those that did not.  
 
Conclusions: Using an assay that measures the ability of the cells to undergo death following 
DNA damage induction by a methylating agent, we were able to assess whether variants in 
MLH1 and MSH2 cause defects in DNA MMR. This assay might be used to help assessing 
the pathogenicity of VUS in MLH1 and MSH2 found in patients with suspected Lynch 
syndrome. 
 
 
KEY-WORDS: Lynch syndrome, mismatch repair (MMR), variant of unknown significance 
(VUS), methylation tolerance 
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INTRODUCTION  
 
Monoallelic germline mutations in one of the 4 human DNA mismatch repair (MMR) genes 
(MLH1, MSH2, MSH6, PMS2) are responsible for Lynch syndrome (LS), formerly known as 
hereditary non-polyposis colorectal cancer. LS is one of the most prevalent inherited cancer 
syndromes in humans and accounts for 1-3% of all colorectal carcinomas (CRC) 
1
. MMR is 
involved in two pathways that are essential for maintaining DNA fidelity, i.e. the correction 
of replication errors that escape proof-reading by DNA polymerases, and the MMR-
dependent cell death following specific DNA damage induced especially by methylating 
agents 
2-6
. Therefore, defective MMR function is linked to increased rates of spontaneous 
somatic mutation, especially in sequences that comprise multiple repeats, thus giving rise to 
microsatellite instability (MSI) 
7-10
. Defective MMR also leads to increased cell tolerance to 
DNA lesions induced by methylating agents, so-called methylation tolerance (MT). In LS 
patients, somatic inactivation of the wildtype allele results in MMR deficiency, leading to 
MSI which in turn drives carcinogenesis 
11
. Accordingly, LS patients have a greatly increased 
risk of developing CRC in their lifetime, as well as extracolonic cancers such as endometrial, 
ovarian, stomach, pancreatic and multiple other cancers 
12
. Analysis for MSI and for loss of 
expression of MMR proteins in tumor tissue by immunohistochemical staining can identify 
patients who may have LS. For a definitive diagnosis of LS, genetic testing should reveal a 
pathogenic germline mutation in a MMR gene. These are found primarily in MLH1 (40%) 
and MSH2 (34%), and to a lesser extent in MSH6 (18%) and PMS2 (8%) 
13
. Identification of a 
high-risk, disease-causing constitutional mutation in the patient then guides the clinical 
management of their entire family, with implications for genetic counseling and pre-
symptomatic surveillance 
14
.  
 
In order to discriminate between variants that are pathogenic and those that are not, the 
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) undertook a 
collaborative project to develop a five-tiered, standardized classification. This was based on 
multiple lines of evidence including variant and family characteristics, as well as the results 
from various functional assays 
15
. Unfortunately, variants with unknown significance (VUS) 
because their pathological impact is unclear represent 31% and 28% of all MLH1 and MSH2 
mutations, respectively 
13
. VUS represent a major clinical challenge since the lack of 
classification precludes LS diagnosis for carriers and their relatives. Variants can be classified 
as VUS for different reasons. Some are VUS because little clinical data is available without 
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reaching a sufficient level of confidence, while others show contradictory evidence. In these 
situations, well-established functional assays can provide further evidence to support a final 
classification especially since they are considered as strong evidence in the classification 
system. Numerous functional assays in different experimental systems have been developed  
16-24
 
among others
, however most are based on model organisms such as bacteria, yeast or mice 
which have intrinsic limitations. Furthermore, most existing in vitro or in vivo tests measure 
specific biochemical or restrictive cell biological properties of variant MMR proteins 
(expression, stability, subcellular location, ability to dimerize, enzymatic activity), but not a 
global approach to MMR functions as reflected by mutation rate, MSI or drug response. To be 
considered relevant, functional studies should be performed using an experimental model that 
mimics as closely as possible the human organism. They should also include appropriate 
controls to allow extensive validation, as well as a global approach to MMR function using in 
vivo experiments 
25
. 
 
We recently developed a functional assay that has been used successfully to characterize 
MMR VUS identified in the context of constitutional MMR deficiency syndrome (CMMRD), 
a rare and severe form of LS caused by bi-allelic germline mutations in MMR genes 
26, 27
. 
This functional test made it possible to diagnose CMMRD syndrome, especially when 
sequencing results were not conclusive due to the presence of VUS 
28, 29
. In the present work  
we have adapted this functional assay, in order to discriminate VUS identified in suspected 
LS patients. This assay based on the DNA damage-induced apoptosis function of MMR, was 
evaluated using a large panel of 88 variants, mainly missense variants, and included a 
validation set of 40 previously classified variants (19 MLH1 and 21 MSH2) and a prospective 
set of 48 VUS (25 MLH1 and 23 MSH2). VUS were selected to correspond to distinct 
prediction scores calculated according to the recommendations of the American College of 
Medical Genetics and Genomics (ACMG) and were based on available clinical, somatic, in 
silico, population and functional data 
30
. As previously shown for CMMRD, we hypothesized 
that our method would be of most value for classifying LS missense variants and in particular 
VUS, with the overall aim of improving the clinical management of LS patients. 
 
 
MATERIALS AND METHODS  
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Selection of the variants 
The present study comprised 44 MLH1 and 44 MSH2 variants. MLH1 variants included 10 
known pathogenic mutations (8 non-synonymous missense mutations and 2 nonsense 
mutations), 9 known neutral alterations (8 non-synonymous and 1 synonymous missense 
alteration) and 25 VUS that are non-synonymous missense alterations. MSH2 variants 
included 10 known pathogenic mutations (9 missense and 1 nonsense mutations), 11 known 
neutral alterations (9 non-synonymous and 2 synonymous missense variants) and 23 VUS. 
For all variants, we checked that no effect on splicing was notified on InSiGHT/French 
databases, or in the absence of functional data by using splicing prediction programs on 
Alamut software. We also ensured that mutations were scattered throughout the protein 
structure. Variants already known to be pathogenic or neutral were selected from the 
InSiGHT and French databases using the following criteria: (i) missense alterations, except 3 
nonsense variants used as controls, (ii) an identical or close classification in both databases 
where possible (i.e. class 4 or 5 for pathogenic and class 1 or 2 for neutral variants), and (iii) a 
relatively high reported frequency. VUS were selected from the InSiGHT and French 
databases according to the following criteria: (i) missense alterations classified as class 3 in 
one or preferably both databases, (ii) a relatively high reported frequency, and (iii) with the 
most available clinical data. In addition, 5 unreported VUS  (4 MLH1 and 1 MSH2) detected 
in suspected-LS patients from the Pitié-Salpétrière hospital were also screened. Furthermore, 
prediction scores were calculated for each VUS in order to select variants with different 
scores. 
 
Prediction scoring 
For each VUS, all available data that matched the ACMG guidelines was compiled as 
follows. Evidence in favor of pathogenicity: functional studies showing a damaging effect 
(strong evidence); variant that induces an amino acid change at the same position as another 
pathogenic variant (moderate evidence); absence or low frequency of the variant in controls 
(GnomAD database) (moderate evidence); and in silico prediction favoring a damaging effect 
(CADD algorithm) (poor evidence). Evidence of benign impact: functional studies showing a 
neutral effect (strong evidence); significant frequency of the variant in controls (GnomAD 
database) (strong evidence); in silico prediction in favor of a neutral effect (CADD algorithm) 
(poor evidence); and co-observation of a pathogenic variant in the individual (poor evidence).  
We developed a scoring method that reflects the weight of each criterion in the rules for 
combining criteria to classify sequence variants as follows: strong evidence was scored as 6 
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points, medium evidence as 2 points and poor evidence as 1 point, with positive values if the 
evidence was in favor of pathogenicity and negative values if the evidence favored a neutral 
effect. 
 
Chemicals 
Cells were exposed to N-Methyl-N’-Nitro-N-Nitrosoguanidine (MNNG) (TCI Europe, 
Zwijndrecht, Belgium). To exclude differences in MNNG cytotoxicity due to variations in 
O6-methylguanine methyltransferase enzyme activity, the latter was abrogated by exposure to 
20 µM O6-benzylguanine (Sigma). All chemicals were dissolved in DMSO to a concentration 
of 20 mM, protected from light and stored at -20°C until used. 
 
Expression vectors 
The complete cDNA for the wild type MLH1 gene (NM_000249.3) and the mCherry reporter 
gene were subcloned into the pIRES vector, placing the expression of the two proteins under 
the control of the strong CMV promoter. The complete cDNA for the wildtype MSH2 gene 
(NM_000251.2), the GFP reporter gene and the IRES sequence were subcloned into the 
pVAX1 vector, placing the expression of the two proteins under the control of the strong 
CMV promoter. The expression constructs for the mutant variants were produced from the 
wildtype vector using site-directed mutagenesis and achieved by ProteoGenix (Schiltigheim 
France).  
 
Cell transfection and cell sorting 
HCT116 (MLH1-deficient), HCT116-ch3 (i.e. HCT116 cell line that had undergone human 
chromosome 3 transfer which makes the cell line MLH1-proficient) 
31
 and LoVo (MSH2-
deficient) cells were grown in a humidified atmosphere containing 5% CO2 in DMEM 
GlutaMAX medium (ThermoFisher) supplemented with 10% fetal calf serum. Exponentially 
growing cells were seeded into 6-well plates in medium supplemented with 1% Penicillin-
Streptomycin and 10% fetal calf serum at a density of 4x10
5
 (HCT116) or 5x10
5
 cells/well 
(LoVo) for 24 hours then transfected with 6 µL TurboFect Transfection Reagent 
(ThermoFisher) mixed with 2 µg plasmid DNA according to the manufacturer’s instructions. 
Medium was removed 6 hours after transfection and fresh medium supplemented with 20 µM 
O6-benzylguanine was added. Cell sorting was performed 24 hours post-transfection based on 
mCherry (for HCT116) or GFP (for LoVo) fluorescence using a MoFlo Astrios Cell Sorter 
(Beckman Coulter).  
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Methylation tolerance assay  
Following cell sorting, mCherry positive HCT116 cells or GFP positive LoVo cells were 
seeded into 12-well plates in medium supplemented with 1% Penicillin-Streptomycin, 20% 
fetal calf serum and 20 µM O6-benzylguanine at a density of 4x10
3 
or
 
10
3 
cells/well, 
respectively. The day after, extemporaneously reconstituted MNNG solution was added at 
0.05, 0.1, 0.5 and 2.5 µmol/L final concentration for the MLH1 training set, and at 0.1 µmol/L 
final concentration for the MLH1 VUS. For MSH2 variants the final MNNG concentration 
was 0.1, 0.5, 1 and 2 µmol/L for the training set and 1 µmol/L for the VUS. Because of the 
short half-life of MNNG in aqueous solution (1 hour), the medium was not replaced after drug 
treatment and 3 rounds of treatment separated by 12 hours were performed. After a total 
incubation time of 12-14 days, HCT116 colonies were fixed and colored in a solution 
containing 6% glutaraldehyde and 0.5% crystal violet. LoVo cells were fixed with methanol 
and stained with a solution of methanol (25%) and crystal violet (0.5%). Colonies were 
counted and the survival fraction was expressed as the number of colonies in the treated 
sample relative to the untreated control sample. All samples were tested in triplicate and each 
experiment was conducted at least in duplicate. 
 
In silico analysis  
All MLH1 and MSH2 variants tested in this work were subjected to in silico analyses using 
the Sorting Intolerant From Tolerant (SIFT), Align GVGD, Mutation Taster and CADD 
algorithms. 
 
Statistical analyses  
Statistical analyses were performed using GraphPad Prism. All statistical tests were two-sided 
except for z-score.  P-values <0.05 were considered significant.  
 
 
RESULTS 
 
Proof of feasibility 
Complementation of MLH1 gene defect  
Briefly, the principle of the assay is as follows: introduction of a MLH1 variant in HCT116 
cells (MLH1-deficient) by transient transfection allows direct investigation of its functional 
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phenotype (functional complementation). To assess only the subset of transfected cells, cells 
were sorted 24h-post transfection to recover only those expressing mCherry, a reporter gene 
contained in the expression vector. Cells were then reseeded, exposed to a methylating agent 
and MMR activity was assessed by a clonogenic assay (Figure 1A). We first checked the 
kinetics of expression of the transgene to verify the proportion of transfected cells remained 
stable for up to 72 hours post-transfection, i.e. for the time cells were exposed to MNNG 
treatments (Supplementary Figure 1A). Then, we investigated the feasibility of the 
experimental procedure by testing whether restoration of cytotoxicity following methylation 
damage could be detected in MLH1-null human CRC HCT116 cells transiently transfected 
with a plasmid containing wildtype MLH1 cDNA sequence. As expected, parental HCT116 
cells lacking MLH1 expression survived mild MNNG selection and were tolerant up to 0.5 μ
M MNNG. Interestingly, the introduction of wildtype MLH1 led to a decreased number of 
colonies that survived selection, indicating restoration of MMR capacity (Figure 1B, 
Supplementary Figure 1B). Cells were about 7-fold more sensitive to MNNG than controls 
(i.e. HCT116 cells transfected with a random sequence, LD50=0.25 vs 1.85 following 1 
MNNG pulse, respectively) (Supplementary Figure 2A).   
Since the literature indicates methylation tolerance is higher than the 7-fold difference 
observed in our assay, we then confirmed the MT assay by using as a control the HCT116 cell 
line that had undergone human chromosome 3 transfer (HCT116-ch3), thus making the cells 
MMR proficient. As expected, we observed that methylation tolerance was up to 62-fold 
higher in this cell line compared to HCT116 cells that were transiently transfected with the 
random cDNA (LD50=0.03 vs LD50=1.85 following 1 MNNG pulse, respectively) (Figure 
1B, Supplementary figure 2A).  
Because transfection is likely to result in multiple copies of the gene in the recipient cells, 
which could affect their response to the drug, we also addressed this issue by separating cells 
that expressed low or high fluorescence intensity (Supplementary Figure 3A). This can be 
considered as an approximate stratification of the cells according to their protein expression 
and hence copy number. HCT116 cells transfected with MLH1 or with a random cDNA 
construct were sorted according to this procedure before screening with the MT assay. No 
significant differences in response were observed between transfected cells that expressed the 
MLH1 plasmid either weakly or strongly (LD50=0.11 vs 0.15 following 1 pulse with MNNG, 
respectively) or between cells transfected with the random cDNA construct (LD50=0.75 vs 
1.14, respectively, P=0.17) (Supplementary Figures 3B and 3C). Therefore, using our 
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experimental conditions we concluded the level of expression of the transgene had no effect 
on the cellular response to the methylating agent. 
 
Complementation of MSH2 gene defect  
The human CRC cell line LoVo containing a large MSH2 homozygous deletion 
32
 was used to 
assess MSH2 variants. As expected, LoVo cells survived mild MNNG selection. When 
transiently transfected with a plasmid containing wildtype MSH2 cDNA sequence, LoVo cells 
were about 4-fold more sensitive than LoVo cells transfected with a random sequence 
(LD50=0.41 vs 1.75 following 1 MNNG pulse, respectively) (Figure 1B and Supplementary 
Figure 2B). 
 
Validation study 
Standardization of the MT assay for MLH1 variants  
We next sought to identify experimental conditions that would best discriminate 10 
previously proven pathogenic MLH1 variants from 9 previously proven non-pathogenic 
MLH1 variants. The former consisted of 8 missense and 2 nonsense variants classified as 
class 5 in the InSiGHT database, while the latter consisted of 8 non-synonymous and 1 
synonymous missense variants classified as class 1 in this database (Supplementary Table 1). 
Following transfection and flow cytometry, sorted cells were reseeded and exposed to a range 
of MNNG concentrations and to different numbers of treatments. The conditions that allowed 
the best discrimination of the 2 groups of variants, i.e. 2 and 3 pulses at 0.1 μM MNNG 
(Figure 2), were used to calculate a mean survival score.  
 
Standardization of the MT assay for MSH2 variants  
The case-control study consisted of 10 previously proven pathogenic MSH2 variants and 11 
previously proven neutral or likely neutral MSH2 variants. The former group comprised 9 
missense and 1 nonsense variants classified as class 4 or class 5 in the InSiGHT database, 
while the latter group comprised 9 non-synonymous and 2 synonymous missense variants 
classified as class 1 or class 2 in the InSiGHT or French (Unicancer) Databases 
33
 
(Supplementary Table 1). Following the same experimental approach than that developed for 
MLH1 variants, it was determined that the 2 sets of MSH2 variants were best discriminated 
using 1 or 2 treatments with 1μM MNNG (Figure 3). 
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MT assay results for MLH1 and MSH2 variants 
Using the above experimental conditions to calculate mean survival scores, all pathogenic 
MLH1 variants displayed a mean survival score above 82.2%, while all non-pathogenic 
MLH1 variants displayed a mean survival score below 55.2% (Figure 4A). A Receiver 
Operating Characteristic (ROC) curve was constructed assuming a binary classification of the 
variants and showed the assay yielded perfect discrimination between pathogenic and neutral 
variants, with 100% sensitivity (69.15-100) and 100% specificity (71.5-100) for a cut-off 
value of 68.7%. Moreover, all pathogenic MSH2 variants displayed a mean survival score 
above 58.90%, whereas the mean survival score of all but one non-pathogenic MSH2 variant 
was below 32.2% (Figure 4B). The ROC curve showed 91.67% sensitivity (61.5-99.8) and 
100% specificity (71.5-100) with a cut-off value of 45.54%. 
 
Prospective study and comparison with previous available data 
Clinical, somatic, in silico, population and functional data for the MLH1 and MSH2 VUS was 
retrieved from public databases (Supplementary Tables 2 and 3). For each variant, this 
information was used to calculate a prediction score in accordance with ACMG 
recommendations
30
 and representing the level of evidence in favor of (positive score) or 
against (negative score) pathogenicity. VUS with different prediction scores were selected for 
testing with our MT assay. 
 
MT assay results for MLH1 VUS 
The functional assay conditions described above were used to evaluate 25 MLH1 missense 
VUS, comprising 21 variants classified as class 3 in the InSiGHT database and 4 unpublished 
variants identified in suspected LS patients and classified as VUS according to ACMG 
guidelines (unpublished data) (Supplementary Table 2). The position of all alterations in the 
MLH1 protein structure is presented in Supplementary Figure 4A. Unlike the clear 
differences seen between known pathogenic and non-pathogenic variants, the VUS exhibited 
a large range of responses to methylation damage (Figure 4A). Two distinct groups were 
observed, with 6 VUS showing a mean survival score above 82.2% and 13 VUS showing a 
score below 55.2%. Thus, according to our validation set of variants, these VUS were 
considered as damaging or neutral, respectively. The mean survival scores of the 6 remaining 
VUS fell in between these values (i.e. 55.2-88.2%) and were significantly different from the 
reference average (P=0.007 for L85P; P=0.003 for L582F and L622P; P=0.004 for L260F; 
P=0.02 for H264Y; P=0.03 for V179D; z-score analysis). Using the cut-off value previously 
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determined by the ROC curve, the first 4 VUS could be classified as “potentially damaging” 
and the last 2 as “potentially neutral”.  
 
Comparison with previous data for MLH1 VUS   
For 6 VUS (marked with an arrow in Figure 5A), there was moderate evidence in favor of 
pathogenicity (prediction score ≥ +9) or against (prediction score ≤ -6) prior to the results of 
the MT assay, based on previous functional data (see Supplementary Table 2). Interestingly, 
for all these VUS our MT results were concordant with previous data. A neutral phenotype 
was indicated for variants A160V, R474Q and E523D and all 3 were classified as non-
damaging for MMR in our screen. In contrast, a pathogenic phenotype was indicated for 
variants G244V, P640L and L582F, with the first 2 classified as damaging and the third as 
potentially damaging in our screen. Although the MT assay does not confer extra evidence to 
classify variants according to current ACMG guidelines 
30
, these results support the relevance 
of our functional assay. For most variants (19/25) there was either little evidence in favor of 
pathogenicity or contradictory evidence prior to the MT assay (-6≤ prediction score ≤5). For 7 
of these variants (L260F, L622P, A539D, W666R, A586D, S106R and L85P), the assay 
results favor pathogenicity, whereas for the 12 other variants they indicate no pathogenicity 
(T116K, V179D, Y126N, I565T, E319K, R474W, R474G, N215S, H264Y, N338S, G454R 
and K618E). The MT assay was therefore clearly able to distinguish this set of variants.  
 
Methylation tolerance assay results for MSH2 VUS 
We next tested a set of 23 MSH2 missense VUS comprising 22 variants previously classified 
as class 3 in the InSiGHT or French databases and one new, unpublished variant 
(Supplementary Table 3). The position of all mutations in the MSH2 protein is presented in 
Supplementary Figure 4B. Two distinct groups were observed (Figure 4B), with 6 VUS 
showing a mean survival score above 58.9% and 15 VUS showing a score below 32.2%. 
These were considered as pathogenic or neutral, respectively. The response of the 2 remaining 
VUS fell in between and differed significantly from the reference average (p=0.017 for L736P 
and p=0.006 for R711Q; z-score analysis). Using the cut-off value determined by the ROC 
curve, they could be identified as “potentially damaging” for MMR.  
 
Comparison with previous data for MSH2 VUS   
Only the A305T MSH2 VUS has been previously assessed with functional assays and this is 
marked with an arrow in Figure 5B. There was moderate evidence against pathogenicity 
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(prediction score = -7) for this VUS and in agreement the MT assay strongly indicated a 
benign impact. For most variants (22/23) there were either little evidence in favor of 
pathogenicity or else contradictory evidence (-1 ≤ prediction score ≤5) prior to the MT assay. 
Our assay discriminates these VUS into MMR abrogating (P622T, V470E, L602P, N671Y, 
A500P, R638G, L736P and R711Q) or neutral (Y856C, G548C, R243Q, E561K, K627N, 
H610N, Y43C, N583S, T33P, T905I, M152T, V342I, A2T and P349A). 
 
 
 
DISCUSSION 
 
Based on our previous successful approach to functionally discriminate MMR VUS in 
CMMRD syndrome 
28
, we hypothesized here that MT could also be used to classify LS 
variants. In a direct comparison with 40 variants previously characterized for pathogenicity, 
our assay correctly classified 39 (97.5%). These results clearly outperform other currently 
employed tools such as in silico prediction tests (Supplementary Figure 5). The only 
discordant result was for the MSH2 (c.593A>G, E198G) mutation, which was classified as 
neutral in the InSiGHT database but pathogenic in our screen. This mutation was identified in 
a Swedish family with five affected members (4 siblings and their father) and with a missense 
MLH3 (T3826C) variant also present in all 4 siblings 
34, 35
. The MSH2 variant segregated with 
CRC diagnosis at ages 29, 40, 62 and 62 years in the family, and was not found in control 
subjects. In agreement with our results, previous functional assays also favored pathogenicity 
for this variant i.e. no MMR, defective interaction with all MSH2 partners, and low protein 
expression in yeast assays 
17, 36
. However, the CRCs did not show MSI. Therefore, the 
classification of this MSH2 variant as neutral is debatable.  
 
The initial results obtained with the MT assay led us to propose a functional and robust test to 
evaluate the impairment of MMR in confirmed LS patients. When applied to a prospective set 
of 48 MLH1 or MSH2 VUS, 40 (83%) could be classified unambiguously as damaging or 
neutral for MMR, whereas 8 showed an intermediate capacity to restore MMR and therefore 
could not be definitively classified. The latter may correspond to weak variants with 
attenuated (but not abrogated) DNA damage response capacity that confer only a moderate 
risk of cancer, as suggested for other genes 
37, 38
 or pathologies 
39
. This hypothesis remains to 
be tested in the context of LS. We next compared the results of the MT assay with the 
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calculated prediction scores that reflect the level of evidence for classification of VUS based 
on all previously available data. For all the VUS in which previous functional data was 
available, the results of the MT assay were in agreement, thus providing further confirmation 
of the relevance of our assay. However for most VUS, there was either little previous 
evidence for pathogenicity or else contradictory evidence. In this subset, our assay makes it 
possible to discriminate VUS that are damaging from those that are neutral. Interestingly, all 
VUS with previous evidence favoring a benign effect were also found to be neutral in the MT 
assay.  
 
The HCT116-ch3 cell line demonstrated a methylation tolerance that was much higher than 
HCT116 cells transfected with MLH1 cDNA. This suggests that MLH1 expression might be 
low in our assay using transient transfection. However, the expression of MLH1 immediately 
following transfection was found to be much higher than in the HCT116-ch3 cell line (results 
not shown). Although we have no definitive explanation for the difference observed in MT, 
one can speculate a possible toxic 
40
 or inhibitory 
41
 effect of over-expressed MLH1 gene, or a 
decreased MLH1 expression in subsequent cell divisions 48h post-transfection (i.e. during 
MNNG treatments). The latter situation could lead to a heterogeneous cell population that 
includes cells with low MLH1 expression. This would result in incomplete MT response 
when using transient transfection compared to the complete MT phenotype observed when 
using the HCT116-ch3 cell line. 
 
Our study has several limitations. Firstly, the expression vector used here may not be suitable 
for assessing the pathogenicity of alleles whose product is functionally equivalent to wildtype, 
but which is expressed at a lower level.  Indeed, the variant is placed under the control of a 
strong promoter resulting in very high, non-physiological expression, similar to most assays 
that use transfection models. Secondly, in contrast with CMMRD syndrome 
28
, variants here 
were evaluated outside the genetic background of the patient and therefore any potential 
additive effects from several variants could be missed. Thirdly, our test assessed one of the 2 
MMR functions. Although both functions (i.e. mismatch repair and DNA damage-induced 
cell death) were found to be linked in the vast majority of MMR mutants explored so far, 
examples of decoupling have been reported for the Msh2
G674A
 and Msh6
T1217D 
mutations in 
mice 
42, 43
 and in MSH-deficient yeast strain models 
44
. 
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We have developed an in vivo functional screen that assesses MMR function in a human cell 
expression model. The MT test has been extensively validated in a case-control cohort for the 
two main MMR genes responsible for LS, namely MLH1 and MSH2. Overall, the robust read-
out demonstrated 95% sensitivity and 100% specificity in classifying MMR variants as 
pathogenic or neutral. In addition, it allowed functional discrimination of MMR VUS beyond 
that of previous methods, being able to discriminate 83% of the VUS tested. This assay is 
simple, reliable, cost-effective and rapid, being performed in 14 to 16 days. Another major 
advantage of our screen is that patient-derived material is not required.  
 
MMR genes are included in the ACMG list for reporting of incidental findings in clinical 
exome and genome sequencing 
45
 and consequently any methods that help to classify VUS in 
these genes are particularly relevant. It is more difficult to classify variants identified by 
sequencing (outside of the known clinical phenotype) without data from functional assays. 
Functional assays can provide strong evidence for assigning the likely functional impact of a 
VUS in the MMR gene classification system. However, such assays are not used routinely in 
the risk assessment of MMR VUS, notably because the reproducibility and performance of 
almost all current MMR functional assays remains to be determined. To our knowledge, the 
present study includes the largest case-control cohort evaluated by a functional assay, 
allowing us to demonstrate its very high sensitivity and specificity. Therefore, we propose 
that each new MLH1 or MSH2 missense variant identified in a suspected LS patient be 
screened using the MT assay in a prospective manner. A study consortium will be required to 
independently validate our method using an additional panel of variants with known neutral 
or pathogenic effect, allowing implementation of this assay in a comprehensive diagnostic 
procedure for LS-associated MLH1 or MSH2 missense variants.   
 
 
FIGURES  
 
FIGURE 1. Functional screen for the characterization of MLH1 or MSH2 variants  
A. Schematic diagram. MLH1 (or MSH2) variants were transiently introduced into the MLH1-
null (or MSH2-null) human colorectal cancer cell line HCT116 (or LoVo). Cells were sorted 
24 hours-post transfection to recover only those expressing mCherry (or GFP), a reporter gene 
contained in the expression vector. Cells were then reseeded and exposed to MNNG (N-
methyl-N'-nitro-N-nitroso-guanidine), a methylating agent that is highly toxic to MMR-
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proficient cells, but only moderately toxic to MMR-deficient cells. Clonogenic survival was 
used as readout for MMR activity. Variants that confer restoration of cytotoxicity to 
methylation damage were assumed to be neutral, whereas variants unable to restore apoptosis 
were assumed to be damaging. All samples were tested in triplicate and each experiment was 
conducted at least twice independently. 
B. Complementation of MMR gene defect. Following transient transfection of HCT116 cells 
with either the MLH1-mCherry or control-mCherry construct (left panels), or LoVo cells with 
either the MSH2-GFP or control-GFP construct (right panels), the transfected cells were 
sorted, reseeded and exposed to 1, 2, or 3 pulses of MNNG treatment for 48 hours, 60 hours 
or 72 hours post-transfection. A clonogenic assay was then carried out. Whereas control cells 
(i.e. cells transfected with random construct, in red) survived mild MNNG selection, cells 
transfected with wildtype MLH1 (or MSH2) containing construct (in green) reversed the MT 
phenotype, indicating restoration of the DNA damage sensing function associated with MMR. 
Response of the non-transfected parental HCT116 (or LoVo) cells (in dark blue) or HCT116-
ch3 cells (in light blue), as well as that of the HCT116-ch3 cells transfected with the control-
random construct (in pink) is shown for comparison. Data represent means ± SD from at least 
2 independent clonogenic experiments, each performed in triplicate.  
 
FIGURE 2. Validation study for MLH1 variants 
Functional screening of a series of proven pathogenic (N=10) and neutral (N=9) MLH1 
variants was performed using increasing concentrations of MNNG. Because of the short half-
life of MNNG in aqueous solution, 1, 2, or 3 pulses of MNNG treatment were performed. The 
best experimental conditions to discriminate pathogenic from neutral variants are indicated 
(red box). Screen results with the control constructs used in the proof of feasibility step (i.e. 
wildtype MLH1 in the neutral cluster or random cDNA in the pathogenic cluster) are 
represented by triangles. All samples were tested in triplicate and each experiment was 
conducted at least twice independently. Student’s t-test was used to compare the means. 
 
FIGURE 3. Validation study for MSH2 variants 
Functional screening of a series of proven pathogenic (N=10) and neutral (N=11) MSH2 
variants was performed using increasing concentrations of MNNG. One, 2, or 3 pulses of 
MNNG treatment were used. The best experimental conditions to discriminate pathogenic 
from neutral variants are indicated (red box). Screen results with the control constructs used 
in the proof of feasibility step (i.e. wildtype MSH2 in the neutral cluster or random cDNA in 
 17 
the pathogenic cluster) are represented by triangles. All samples were tested in triplicate and 
each experiment was conducted at least twice independently. Student’s t-test was used to 
compare the means. 
 
FIGURE 4. Functional MT screen for the detection of damaging MLH1 and MSH2 variants 
(validation and prospective sets)  
A. A total of 44 MLH1 variants including 10 proven pathogenic variants and 9 proven neutral 
variants (validation set), as well as 25 VUS (prospective set) were tested using the functional 
screen. The mean survival score represents the average survival fraction after 2 and 3 
treatments with 0.1 μM MNNG.  
B. A total of 44 MSH2 variants including 10 proven pathogenic variants and 11 proven 
neutral variants (validation set), as well as 23 VUS (prospective set) were tested using the 
functional screen. The mean survival score represents the average survival fraction after 1 and 
2 treatments with 1 μM MNNG.  
The grey area corresponds to the 5% values that differed significantly from the average as 
defined by the z-score. The cut-off value as determined by the ROC curve in the validation set 
is represented by the dotted line. 
 
 
FIGURE 5. Evidence for or against pathogenicity for the 48 VUS screened with the MT 
assay 
For each MLH1 (A) or MSH2 (B) VUS, all available data was assigned as strong, moderate or 
poor evidence in favor of either pathogenicity or a benign impact, according to the 
recommendations of the American College of Medical Genetics and Genomics (ACMG) 
30
. 
For graphic representation, a scoring system was established that reflects the weight of each 
criterion in the rules used for combining criteria to classify sequence variants. i.e. +6 points 
for strong, +2 points for moderate and +1 point for poor evidence of pathogenicity; -6 points 
for strong and -1 point for poor evidence of a benign impact.  
Light blue bars represent the level of evidence in favor of pathogenicity (positive values) or in 
favor of a benign impact (negative values) for each VUS based on all previously available 
data. Dark blue bars indicate the level of evidence in favor of pathogenicity (positive values) 
or in favor of a benign impact (negative values) for each VUS conferred by the results of the 
MT assay. For the 7 VUS marked with an arrow, there was moderate evidence in favor of or 
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against pathogenicity prior to the MT assay, due to the existence of previous functional data. 
Although the MT assay results supported the published data for all of these 7 VUS, it did not 
confer additional points according to the ACMG classification system. Consequently, the dark 
blue bar is shown next to the light blue bar for these 7 variants. VUS in italics are classified 
using the MT assay as potentially damaging or potentially neutral. 
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